HUM - Humana Inc.

NYSE - NYSE Delayed Price. Currency in USD
381.87
+0.29 (+0.08%)
At close: 4:04PM EDT

381.87 0.00 (0.00%)
After hours: 4:19PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close381.58
Open382.76
Bid383.10 x 800
Ask383.57 x 800
Day's Range381.17 - 390.39
52 Week Range208.25 - 412.70
Volume584,439
Avg. Volume970,585
Market Cap50.486B
Beta (5Y Monthly)0.87
PE Ratio (TTM)19.56
EPS (TTM)19.52
Earnings DateAug 05, 2020
Forward Dividend & Yield2.50 (0.66%)
Ex-Dividend DateJun 29, 2020
1y Target Est432.87
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
25% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why the Earnings Surprise Streak Could Continue for Humana (HUM)
    Zacks

    Why the Earnings Surprise Streak Could Continue for Humana (HUM)

    Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • 3 Health Insurers Poised for a Bull Run in the Second Half
    Zacks

    3 Health Insurers Poised for a Bull Run in the Second Half

    We shortlist three health insurance stocks for the second half of 2020 that should enhance your portfolio, given their solid fundamentals.

  • Business Wire

    Humana Inc. to Release Second Quarter 2020 Results on August 5, 2020

    Humana Inc. (NYSE: HUM) will release its financial results for the second quarter 2020 (2Q20) on Wednesday, August 5, 2020 at 6:30 a.m. eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2020.

  • Were Hedge Funds Right About Souring On Humana Inc (HUM)?
    Insider Monkey

    Were Hedge Funds Right About Souring On Humana Inc (HUM)?

    We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]

  • Molina Healthcare (MOH) Acquires to Boost Medicaid Business
    Zacks

    Molina Healthcare (MOH) Acquires to Boost Medicaid Business

    Molina Healthcare (MOH) buys certain assets of YourCare Health Plan to enrich its portfolio and perk up its Medicaid business.

  • Investopedia

    Health Insurance Stocks in 'Sweet Spot' Despite Pandemic

    Health insurance stocks are trading close to all-time highs due to poorly understood benefits of the pandemic.

  • Humana's Testing Initiative to Aid Members Amid Coronavirus
    Zacks

    Humana's Testing Initiative to Aid Members Amid Coronavirus

    Humana (HUM) collaborates with Walmart, Quest, LabCorp for COVID-19 testing.

  • 3 Healthcare Insurance Stocks With Great Dividends and More
    Motley Fool

    3 Healthcare Insurance Stocks With Great Dividends and More

    Insurance companies know how to play it safe. These three big players in healthcare all offer nice income.

  • Insurer Humana teams up with Walmart, Quest, LabCorp for COVID-19 testing
    Reuters

    Insurer Humana teams up with Walmart, Quest, LabCorp for COVID-19 testing

    U.S. health insurer Humana Inc will offer its members at-home COVID-19 test collection kits, as well as provide access to drive-through testings at the hundreds of neighborhood markets of Walmart Inc, it said on Tuesday. For drive-through testing, the insurer said it has tied up with the retail chain and Quest Diagnostics. Humana said new testing sites at Walmart pharmacies will be added between now and August for pharmacist-observed testing.

  • Business Wire

    Humana to Offer LabCorp At-Home COVID-19 Test Collection and Collaborate with Walmart and Quest Diagnostics to Offer Drive-Thru Testing for Humana Members

    Leading health and well-being company Humana Inc. (NYSE: HUM) announced a pilot home-testing program today that will enable at-home COVID-19 test collection for members, making Humana the first insurer to offer LabCorp’s at-home test-collection kits. Humana also announced an innovative new collaboration with Walmart and Quest Diagnostics to help members more easily get tested – becoming the first health care company to offer its members drive-thru testing at hundreds of Walmart Neighborhood Market drive-thru pharmacy locations across the country. Humana will continue to waive member costs related to COVID-19 diagnostic tests.

  • Magellan Health's Initiative to Help Fight Mental Illnesses
    Zacks

    Magellan Health's Initiative to Help Fight Mental Illnesses

    Magellan Health (MGLN) takes initiatives to help individuals combat mental health woes during the coronavirus pandemic.

  • DispatchHealth Raises $135.8 Million in Series C Financing
    PR Newswire

    DispatchHealth Raises $135.8 Million in Series C Financing

    DispatchHealth, a provider of tech-enabled in-home health care, today announced the closing of $135.8 million growth capital financing. The Series C round was led by Optum Ventures and included participation from existing investors Alta Partners, Questa Capital, Echo Health Ventures, new investors Oak HC/FT, Humana Inc. (NYSE: HUM) and additional strategic investors.

  • Money Won’t Be Made in These 2 Healthcare Stocks
    Insider Monkey

    Money Won’t Be Made in These 2 Healthcare Stocks

    HealthInvest Partners AB is the investment management company of HealthInvest Small & MicroCap Fund. HealthInvest Partners recently released its April month Investor Letter, a copy of which you can download here. HealthInvest Small & MicroCap Fund rose 9.1% in April, which was broadly in line with its benchmark index. You should check out HealthInvest Partners […]

  • Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population
    Business Wire

    Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population

    Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population

  • Humana's Initiatives to Help Dental Providers Manage Costs
    Zacks

    Humana's Initiatives to Help Dental Providers Manage Costs

    Humana (HUM) takes certain measures to provide cushion to dental care providers in coping with high costs during the plaguing pandemic.

  • Business Wire

    Humana Inc. to Present at the BMO Prescriptions for Success Healthcare Conference

    Humana Inc. (NYSE: HUM) announced today that Brian A. Kane, Chief Financial Officer, will make a presentation to investors at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020, at 8:00 a.m. Eastern time.

  • Humana Announces Monthly Stipend to Reduce Costs for Dental Providers During Pandemic
    Business Wire

    Humana Announces Monthly Stipend to Reduce Costs for Dental Providers During Pandemic

    Humana Announces Monthly Stipend to Reduce Costs for Dental Providers During Pandemic

  • Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 30%
    TipRanks

    Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 30%

    The healthcare sector has held up strong amid the global pandemic, yet not all names have escaped COVID-19's grasp. For several companies inhabiting the space, historically low levels of utilization for both traditional procedures and services as a result of COVID-19 and the expected mass consumption after restrictions are loosened have presented significant headwinds. It doesn’t help that unemployment also poses risks. Against this backdrop, investment firm Goldman Sachs took a deep dive into the space, hoping to get a better sense of where healthcare stocks stand during these unprecedented times. Given the uncertainty still hanging in the balance, the firm points out that investments in the sector aren’t without risk. That being said, it argues that some names are poised to deliver a strong performance in the long run. With this in mind, we wanted to take a closer look at two healthcare stocks that just received Goldman Sachs’ stamp of approval, with the firm projecting upside potential of more than 30% for each. Using TipRanks’ database, we found out that the rest of the Street is also on board as both have earned a “Strong Buy” consensus rating. Adaptive Biotechnologies Corporation (ADPT) Taking advantage of the inherent biology of the immune system, Adaptive Biotechnologies wants to transform the way diseases are diagnosed and treated. Based on the strength of the sequencing and diagnostic company’s portfolio, Goldman Sachs believes that now is the time to pull the trigger. Representing the firm, five-star analyst Salveen Richter tells clients ADPT offers commercial technologies designed for specific use cases. Its immunoSEQ platform is used in academic and biopharma research while clonoSEQ was developed for a clinical setting, with the latter able to detect minimal residual disease (MRD). This will be expanded to include blood-based (liquid biopsy) testing (versus bone marrow), and will increasingly be used as a primary endpoint during clinical trials. The good news doesn’t end there. Richter argues that its clinical diagnostic product pipeline, which includes immunoSEQ Dx from its collaboration with Microsoft, as well as its drug discovery pipeline that features the Amgen-partnered COVID-19 program, are capable of driving significant upside. On top of this, ADPT made its foray into the world of drug development, collaborating with Genentech on the development of cellular therapies in oncology. Going beyond this agreement, Richter thinks the company could potentially pursue other opportunities in cell therapy separate from the partnership, including other disease states like autoimmune diseases and cancer vaccines. “We view the collaborations with industry-defining leaders such as Genentech, MSFT and AMGN as validating to ADPT’s approach to advance immune-driven medicine, and note the Genentech agreement provides ADPT with significant milestone (potentially up to $1.8 billion in aggregate) and royalty payments on future sales of drugs that are created by utilizing ADPT’s platform,” Richter explained. To sum up her take, Richter noted, “Overall, we have a positive view on the fundamental trajectory of the business and innovative platform technology, and see immunoSEQ Dx and drug discovery as significant value drivers in the future, supported by steady revenue growth from ADPT’s base businesses for clonoSEQ and immunoSEQ.” Based on all of the above, it’s no wonder Richter kicked off her coverage of ADPT by publishing a Buy recommendation. With a $60 price target, shares could climb 55% higher in the next twelve months. (To watch Richter’s track record, click here) All in all, other analysts echo Richter’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $52 average price target, the upside potential comes in at 34%. (See Adaptive Biotechnologies stock analysis on TipRanks) Humana Inc. (HUM) While acknowledging that health insurance company Humana has faced newer entrants in the Medicare Advantage (MA) market, its mix of business and sheer size make it a stand-out, in Goldman Sachs’ opinion. Weighing in on the stock for the firm, five-star analyst Robert Jones sees HUM’s scale, brand reputation and provider infrastructure as positioning it to “continue to gain share in the fastest growing vertical of Managed Care.” He added, “Importantly, continued growth in this end-market also has a more pronounced impact to HUM’s bottom line versus other managed care organizations (MCOs) given HUM’s more concentrated exposure to MA.” In the past, the company’s exposure within the MA space has been “an attractive value proposition given the secular growth drivers that are present”, but now, the segment looks even stronger, according to Jones. For the most part, MA has managed to escape the impacts of COVID-19, which could help drive multiple expansion. Another key component of Jones’ bullish thesis is its primary care strategy. As part of this approach, HUM has opened payor-agnostic, senior-focused primary care centers, with it building over 260 of these owned, joint venture or alliance primary care centers. The company also announced another 35 are set to open in 2020. Expounding on the benefits of its strategy, Jones commented, “Looking forward, we think HUM’s primary care strategy could be a meaningful growth lever for the company. In our view, the opportunity from these centers is threefold, in that it could help HUM (1) recruit and retain MA members, (2) increase the profitability of the members that are managed under these value-based arrangements, and (3) recognize long-term EBITDA growth from the providers themselves.” Of these, the analyst believes the possibility of stronger growth and retention, as well as improved member profitability are “the most meaningful.” Everything HUM has going for it prompted Jones to take a bullish stance. In addition to initiating coverage with a Buy rating, he set a $510 price target. This target suggests shares could surge 31% in the next year. (To watch Jones’ track record, click here) Turning now to the rest of the Street, most other analysts are on the same page. With 12 Buys and 2 Holds assigned in the last three months, the word on the Street is that HUM is a Strong Buy. Additionally, the $435.50 average price target brings the upside potential to 12%. (See Humana stock analysis on TipRanks)

  • Barrons.com

    In a Changed World for Health Insurers, Goldman Sachs Likes UnitedHealth and Humana Stock

    Goldman likes the managed care companies that are big and involved with Medicare supplemental insurance.

  • Humana Announces Support for Louisville to Help Rebuild and Unite City
    Business Wire

    Humana Announces Support for Louisville to Help Rebuild and Unite City

    Humana announces support for Louisville to help rebuild and unite city.

  • Humana's Unit to Launch Primary Care Centers for Seniors
    Zacks

    Humana's Unit to Launch Primary Care Centers for Seniors

    Humana's (HUM) arm Partners in Primary Care to unveil 20 new medical care centers with focus to serve seniors. There are further plans to extend reach in Houston with 10 more centers.

  • Teladoc: Leading the Way in Telemedicine
    GuruFocus.com

    Teladoc: Leading the Way in Telemedicine

    Use of telehealth as alternative to face-to-face visits largely being driven by coronavirus pandemic Continue reading...

  • Partners in Primary Care Begins Major Three-Year Expansion with 20 New Centers
    Business Wire

    Partners in Primary Care Begins Major Three-Year Expansion with 20 New Centers

    Partners in Primary Care Begins Major Three-Year Expansion with 20 New Centers